First clinical trials of DNA vaccine based on TERT applied in cancer patients reported it to be safe, well tolerated, and immunogenic [28,29], immunization resulting in disease stabilization in 58% of patients with relapsed or refractory cancers [28]. This evidence concerns the gene TERT and cancer.